Bio-Techne Corp. closed 31.67% below its 52-week high of $85.57, which the company reached on May 15th. The stock underperformed when compared to some of its competitors Tuesday, ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

Since the announcement, BIO stock has lost 9.5% to $277.16 last Friday. The company has been gaining synergies from its digital PCR platform’s increased penetration in advanced clinical ...

Research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Nuvation Bio in a report released on Monday, March 10th. HC Wainwright analyst R. Burns now expects ...

The figure missed the Zacks Consensus Estimate marginally by 0.2%. Following the earnings announcement, BIO stock declined 0.4% in yesterday’s after-market trading. Revenues of $667.5 million ...

Tevogen Bio (NASDAQ:TVGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a ...

Mustang Bio (NASDAQ:MBIO) stock plunged 29% post-market after the company announced it has exited the lease for its manufacturing facility in Worcester, Mass. and relocated its headquarters to ...

Explore Instil Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TIL. Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over ...

(NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology ... of directors of the Company approved a 1-for-17 reverse stock split (the “Reverse Split”) of the Company’s common ...

Gossamer Bio develops Seralutinib ... potentially prove that its PVR reduction is competitive. In my view, the stock is basically a binary bet on Seralutinib, which will give us top-line data ...